● BREAKING NEWS
HealthBiz
search
Menu
Pharma Nov 05, 2026 · min read

Lupin Appoints Akhil Gupta as Independent Director for Five-Year Term

Team HealthBiz

HealthBiz

Lupin Appoints Akhil Gupta as Independent Director for Five-Year Term

Mumbai-based pharmaceutical major Lupin Limited has appointed business leader and Chartered Accountant Akhil Gupta as an Additional Director (Non-Executive, Independent), strengthening its board with more than four decades of experience in corporate strategy, finance, governance and business development.

Lupin Limited has announced the appointment of Akhil Gupta as an Additional Director (Non-Executive, Independent) to its Board, effective November 3, 2026.

The appointment was unanimously approved by the company's Board of Directors following a recommendation from the Nomination and Remuneration Committee. Gupta will serve a five-year term as an Independent Director, from November 3, 2026, to November 2, 2031, subject to approval by the company's members.

Extensive Experience in Corporate Leadership

A qualified Chartered Accountant, Akhil Gupta brings over 40 years of professional experience spanning corporate strategy, business development, financial management, mergers and acquisitions, and corporate governance. He has also completed the Advanced Management Program at Harvard Business School, Harvard University.

During his career, Gupta served as Vice Chairman of Bharti Enterprises Limited, where he played a significant role in the group's expansion through organic growth and strategic acquisitions.

He currently holds several prominent corporate positions, including Non-Executive Independent Chairman of 360 ONE WAM Limited, Coforge Limited and Valuedrive Technologies Limited (Spinny). He also serves as an Independent Director at Lodha Developers Limited and Zepto Limited, and as a Nominee Director of Acevector Limited.

Contributions Across Industry and Policy

Beyond his corporate board responsibilities, Gupta is the President of the Telecom Sector Skill Council and Chairman of Inversion Advisory Services.

He has also been associated with the Confederation of Indian Industry (CII), including its National Committee on Telecom and Broadband and Task Force on Insolvency and Bankruptcy.

His previous industry and policy engagements include leadership at the Digital Infrastructure Providers Association and participation in advisory committees associated with the Insolvency and Bankruptcy Board of India and the Government of India's Insolvency Law Committee.

Through Inversion Advisory Services, he advises businesses across sectors such as infrastructure, renewable energy, automobiles, tourism and other industries.

Recognitions and Industry Achievements

Gupta has received several professional distinctions during his career, including the EY Entrepreneur of the Year Award in the Entrepreneur CEO category, CA Global Achiever Award, CA Business Achiever Award and CEO of the Year Award.

His other recognitions include Lifetime Achievement Awards from ET Telecom, Voice & Data, the Institute of Chartered Accountants of India (ICAI) and Amity University, along with multiple CNBC-TV18 Best CFO Awards. He has also been inducted into the CFO India Hall of Fame.

Lupin's Board Strengthening Strategy

Commenting on the appointment, Manju D. Gupta, Chairperson of Lupin, welcomed Akhil Gupta to the Board and highlighted his strategic perspective, financial expertise, governance experience and track record of building large businesses.

The company stated that his experience would contribute to Lupin's efforts to strengthen its global position and pursue its next phase of growth.

Headquartered in Mumbai, Lupin Limited operates across India, the United States, other developed markets and emerging markets, with its products available in more than 100 markets.

Its portfolio includes generics, complex generics, specialty medicines and biosimilars. The company has significant operations across cardiovascular, respiratory, diabetes, gastrointestinal and women's health segments.

Lupin operates 15 manufacturing facilities and six research centres, supported by a workforce of more than 26,000 employees. Its broader healthcare operations also include diagnostics, digital health, patient-support programmes and disease management initiatives.

The appointment comes as Lupin continues to strengthen its corporate governance and board-level leadership to support its global pharmaceutical business.

Written by

Team HealthBiz